Molecular and clinical characteristics at diagnosis and clinical outcome of CN-AML patients according to BAALC status
| Characteristic . | Overall, n = 172 . | Low BAALC, n = 86 . | High BAALC, n = 86 . | P* . |
|---|---|---|---|---|
| FLT3-ITD, no. (%) | .04 | |||
| Negative | 110 (64) | 62 (72) | 48 (56) | |
| Positive | 62 (36) | 24 (28) | 38 (44) | |
| NPM1, no. (%) | <.001 | |||
| Wild-type | 51 (32) | 14 (17) | 37 (48) | |
| Mutated | 109 (68) | 69 (83) | 40 (52) | |
| CEBPA, no. (%) | .003 | |||
| Wild-type | 107 (79) | 60 (90) | 47 (68) | |
| Mutated | 29 (21) | 7 (10) | 22 (32) | |
| MLL-PTD, no. (%) | .009 | |||
| Negative | 155 (91) | 83 (97) | 72 (85) | |
| Positive | 16 (9) | 3 (3) | 13 (15) | |
| FLT3-TKD, no. (%) | .005 | |||
| Negative | 148 (91) | 71 (85) | 77 (97) | |
| Positive | 15 (9) | 13 (15) | 2 (3) | |
| ERG expression†, no. (%) | .05 | |||
| Low | 100 (63) | 54 (71) | 46 (55) | |
| High | 59 (37) | 22 (29) | 37 (45) | |
| Age, y | .30 | |||
| Median | 46 | 47 | 45 | |
| Range | 18-59 | 19-59 | 18-59 | |
| Sex, no. of males (%) | 79 (46) | 39 (45) | 40 (47) | 1.0 |
| Race, no. (%) | 1.0 | |||
| White | 153 (91) | 76 (90) | 77 (91) | |
| Nonwhite | 16 (9) | 8 (10) | 8 (9) | |
| Hemoglobin, g/L | .99 | |||
| Median | 92 | 92 | 93 | |
| Range | 46-136 | 49-136 | 46-133 | |
| Platelet count, ×109/L | .34 | |||
| Median | 56 | 55 | 57 | |
| Range | 5-445 | 5-380 | 7-445 | |
| WBC, ×109/L | .09 | |||
| Median | 26.1 | 29.6 | 23.5 | |
| Range | 0.8-295.0 | 1.6-295.0 | 0.8-172.8 | |
| Blood blasts, % | .30 | |||
| Median | 57 | 55 | 60 | |
| Range | 0-97 | 0-97 | 0-95 | |
| Bone marrow blasts, % | .74 | |||
| Median | 65 | 65 | 65 | |
| Range | 10-99 | 10-99 | 21-99 | |
| Centrally reviewed FAB classification, no. (%) | .006 | |||
| M0 | 3 (2) | 1 (2) | 2 (3) | |
| M1 | 30 (25) | 11 (18) | 19 (32) | |
| M2 | 42 (35) | 18 (30) | 24 (40) | |
| M4 | 29 (24) | 18 (30) | 11 (18) | |
| M5 | 12 (10) | 11 (18) | 1 (2) | |
| M6 | 2 (2) | 0 (0) | 2 (3) | |
| Unclassified | 3 (2) | 2 (3) | 1 (2) | |
| Complete remission rate, no. (%) | 145 (84) | 77 (90) | 68 (79) | .09 |
| Disease-free survival | .05 | |||
| Median, y | 2.0 | Not reached | 1.3 | |
| Disease-free at 3 y, % (95% CI) | 46 (38-54) | 53 (41-64) | 39 (27-50) | |
| Overall survival | .002 | |||
| Median, y | 3.4 | Not reached | 1.6 | |
| Alive at 3 y, % (95% CI) | 51 (43-58) | 59 (48-69) | 42 (31-52) |
| Characteristic . | Overall, n = 172 . | Low BAALC, n = 86 . | High BAALC, n = 86 . | P* . |
|---|---|---|---|---|
| FLT3-ITD, no. (%) | .04 | |||
| Negative | 110 (64) | 62 (72) | 48 (56) | |
| Positive | 62 (36) | 24 (28) | 38 (44) | |
| NPM1, no. (%) | <.001 | |||
| Wild-type | 51 (32) | 14 (17) | 37 (48) | |
| Mutated | 109 (68) | 69 (83) | 40 (52) | |
| CEBPA, no. (%) | .003 | |||
| Wild-type | 107 (79) | 60 (90) | 47 (68) | |
| Mutated | 29 (21) | 7 (10) | 22 (32) | |
| MLL-PTD, no. (%) | .009 | |||
| Negative | 155 (91) | 83 (97) | 72 (85) | |
| Positive | 16 (9) | 3 (3) | 13 (15) | |
| FLT3-TKD, no. (%) | .005 | |||
| Negative | 148 (91) | 71 (85) | 77 (97) | |
| Positive | 15 (9) | 13 (15) | 2 (3) | |
| ERG expression†, no. (%) | .05 | |||
| Low | 100 (63) | 54 (71) | 46 (55) | |
| High | 59 (37) | 22 (29) | 37 (45) | |
| Age, y | .30 | |||
| Median | 46 | 47 | 45 | |
| Range | 18-59 | 19-59 | 18-59 | |
| Sex, no. of males (%) | 79 (46) | 39 (45) | 40 (47) | 1.0 |
| Race, no. (%) | 1.0 | |||
| White | 153 (91) | 76 (90) | 77 (91) | |
| Nonwhite | 16 (9) | 8 (10) | 8 (9) | |
| Hemoglobin, g/L | .99 | |||
| Median | 92 | 92 | 93 | |
| Range | 46-136 | 49-136 | 46-133 | |
| Platelet count, ×109/L | .34 | |||
| Median | 56 | 55 | 57 | |
| Range | 5-445 | 5-380 | 7-445 | |
| WBC, ×109/L | .09 | |||
| Median | 26.1 | 29.6 | 23.5 | |
| Range | 0.8-295.0 | 1.6-295.0 | 0.8-172.8 | |
| Blood blasts, % | .30 | |||
| Median | 57 | 55 | 60 | |
| Range | 0-97 | 0-97 | 0-95 | |
| Bone marrow blasts, % | .74 | |||
| Median | 65 | 65 | 65 | |
| Range | 10-99 | 10-99 | 21-99 | |
| Centrally reviewed FAB classification, no. (%) | .006 | |||
| M0 | 3 (2) | 1 (2) | 2 (3) | |
| M1 | 30 (25) | 11 (18) | 19 (32) | |
| M2 | 42 (35) | 18 (30) | 24 (40) | |
| M4 | 29 (24) | 18 (30) | 11 (18) | |
| M5 | 12 (10) | 11 (18) | 1 (2) | |
| M6 | 2 (2) | 0 (0) | 2 (3) | |
| Unclassified | 3 (2) | 2 (3) | 1 (2) | |
| Complete remission rate, no. (%) | 145 (84) | 77 (90) | 68 (79) | .09 |
| Disease-free survival | .05 | |||
| Median, y | 2.0 | Not reached | 1.3 | |
| Disease-free at 3 y, % (95% CI) | 46 (38-54) | 53 (41-64) | 39 (27-50) | |
| Overall survival | .002 | |||
| Median, y | 3.4 | Not reached | 1.6 | |
| Alive at 3 y, % (95% CI) | 51 (43-58) | 59 (48-69) | 42 (31-52) |
FLT3-ITD indicates internal tandem duplication of the FLT3 gene; MLL-PTD, partial tandem duplication of the MLL gene; FLT3-TKD, tyrosine kinase domain mutation of the FLT3 gene; WBC, white blood cell count; FAB, French-American-British; and CI, confidence interval.
P value compares differences in molecular and clinical characteristics at diagnosis as well as in clinical outcome between patients with low and high BAALC expression values.
For patients on protocol 9621, cut point is the same as in Marcucci et al.15 For patients on protocol 19808, cut point is the same as in Marcucci et al.16